Centessa Pharmaceuticals Plc SEC Filings

Director Arjun Goyal of Centessa Pharmaceuticals was granted 40,000 stock options on June 20, 2025. The options have the following key terms:

• Exercise price set at $12.43 per share
• Expiration date of June 20, 2035
• Vesting occurs at earlier of: - First anniversary of grant date - Next annual shareholder meeting
• Options convert to ordinary shares (which may be represented as American Depositary Shares)
• Vesting conditional on continued service as director

This Form 4 filing, signed by attorney-in-fact Iqbal Hussain, represents a standard director compensation equity grant, suggesting continued commitment to aligning director interests with shareholders through long-term equity incentives.

Form 4 filing reveals that Mary Lynne Hedley, Director at Centessa Pharmaceuticals, was granted 40,000 share options on June 20, 2025. The stock options have an exercise price of $12.43 per share and will expire on June 20, 2035.

Key details of the option grant:

• Vesting occurs at the earlier of: (1) first anniversary of grant date or (2) next annual shareholder meeting
• Vesting is contingent on continued service as director
• Options are convertible into ordinary shares, which may be represented as American Depositary Shares (1:1 ratio)
• Direct ownership form reported

This grant appears to be part of the company's director compensation program. No other securities transactions were reported in this filing.

Form 4 filing reveals that Samarth Kulkarni, Director at Centessa Pharmaceuticals, received a stock option grant on June 20, 2025. Key details:

• Granted 40,000 stock options to purchase ordinary shares at an exercise price of $12.43 per share
• Options will vest in full at the earlier of: - First anniversary of grant date - Next annual shareholder meeting
• Options expire on June 20, 2035
• Vesting conditional on continued service as director
• Ordinary shares may be represented by American Depositary Shares (ADS), with each ADS representing one ordinary share

This equity compensation grant aligns with standard director compensation practices and aims to align the director's interests with shareholders. The filing was signed by Iqbal Hussain as attorney-in-fact on June 24, 2025.

Centessa Pharmaceuticals director Carol Stuckley received a stock option grant on June 20, 2025. The derivative securities transaction details include:

• Granted 40,000 share options to purchase ordinary shares
• Exercise price set at $12.43 per share
• Options expire on June 20, 2035
• Vesting occurs at earlier of:
  • First anniversary of grant date
  • Next annual shareholder meeting

The options are subject to continued service as director through the vesting date. Each ordinary share may be represented by one American Depositary Share (ADS). The transaction was reported via Form 4 filing with attorney-in-fact signature dated June 24, 2025.

Centessa Pharmaceuticals plc (CNTA) – Form 4 insider filing

Director Brett I. W. Zbar reported the grant of an option to acquire 40,000 ordinary shares of Centessa Pharmaceuticals on 20 June 2025 at an exercise price of $12.43 per share. The instrument is classified as a “Share Option (right to buy)” and is held directly.

The option vests in full on the earlier of (i) the first anniversary of 20 June 2025 or (ii) the Company’s next annual meeting of shareholders, subject to Dr. Zbar’s continued service as director. The option carries a 10-year term with an expiration date of 20 June 2035. Following the grant, Dr. Zbar reports beneficial ownership of 40,000 derivative securities and no change to non-derivative share ownership was disclosed.

The filing notes that the option is held by Dr. Zbar solely for the benefit of General Atlantic Service Company, L.P.; he disclaims beneficial ownership except to the extent of any pecuniary interest.

No open-market purchases or sales of CNTA ordinary shares or ADSs were reported, and the filing does not indicate transactions made under a Rule 10b5-1 plan.

Centessa Pharmaceuticals plc (NASDAQ: CNTA) has submitted a Form 144 notifying the SEC of a proposed sale of 12,000 common shares by an insider through UBS Financial Services on 24 June 2025. The estimated aggregate market value is $168,218.40, implying a per-share price of roughly $14.02. The filing states that 133,618,774 shares are outstanding, meaning the planned sale represents less than 0.01 % of total shares. The seller acquired the shares the same day via a cash-settled stock-option exercise.

The insider previously sold a combined 6,000 shares over the past three months for total proceeds of $84,012.01. No additional operational or financial data were disclosed, and the signatory affirms awareness of no undisclosed material adverse information. Given the modest size relative to the float and the routine nature of Form 144 notices, the event is unlikely to materially affect Centessa’s fundamentals or valuation.

Centessa Pharmaceuticals plc (CNTA) – Form 3 Initial Statement of Beneficial Ownership

The filing discloses that Mario Alberto Accardi, President of the company’s Orexin Program, beneficially owns 216,485 ordinary shares, including 25,150 restricted share units. All holdings are reported as direct.

Accardi also holds a series of employee share options covering a total of 323,425 ordinary shares with exercise prices ranging from $3.85 to $16.90 and expirations between 2032-2035. The options vest monthly over four-year periods or upon performance goal achievement, starting on various dates from March 2022 through March 2025.

No transactions were reported; this Form 3 simply establishes the insider’s starting ownership position as of 13 June 2025.

Centessa Pharmaceuticals CEO Saurabh Saha executed significant stock transactions on June 20, 2025. The transactions involved:

• Exercised 55,000 stock options at $3.85 per share
• Subsequently sold 55,000 ordinary shares at weighted average price of $12.63 per share
• Sales were executed under a pre-established Rule 10b5-1 trading plan from May 16, 2024

Post-transactions, Saha holds 221,017 ordinary shares directly and 38,000 shares indirectly through a trust. He retains 205,000 stock options exercisable until February 2033. The options vest monthly at 1/48th rate starting March 2023. This transaction resulted in an approximate gross profit of $483,000 before taxes and fees.